MCID: DRM014
MIFTS: 60

Dermatofibrosarcoma Protuberans malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Cancer diseases

Aliases & Classifications for Dermatofibrosarcoma Protuberans

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dermatofibrosarcoma Protuberans:

Name: Dermatofibrosarcoma Protuberans 52 11 48 24 25 54 27 50 13 68
Dermatofibrosarcoma 25 50 39 68
Dfsp 48 25 54
Metastatic Dermatofibrosarcoma Protuberans 48 68
 
Giant Cell Fibroblastoma 48 68
Familial Dermatofibrosarcoma Protuberans 48
Darier-Hoffmann Tumor 25
Darier-Ferrand Tumor 25

Characteristics:

Orphanet epidemiological data:

54
dermatofibrosarcoma protuberans:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: adult

Classifications:

Orphanet: 54 
Rare skin diseases


External Ids:

OMIM52 607907
Disease Ontology11 DOID:3507
MeSH39 D018223
Orphanet54 ORPHA31112
MESH via Orphanet40 C538219
UMLS via Orphanet69 C0392784
ICD10 via Orphanet31 C49.9

Summaries for Dermatofibrosarcoma Protuberans

About this section
NIH Rare Diseases:48 Dermatofibrosarcoma protuberans is an uncommon cancer in which tumors arise in the deeper layers of skin. The tumor usually starts as a small, firm patch of skin; it may be purplish, reddish, or flesh-colored. It is commonly found on the torso, usually in the shoulder and chest area. The tumor typically grows slowly but has a tendency to recur after being removed. It rarely spreads to other parts of the body. The cause of DFSP is unknown, but injury to the affected skin may be a predisposing factor. Treatment usually involves surgically removing the tumor. If the tumor is unable to be removed completely, additional therapy may be needed. Regular follow-up is important to monitor for recurrence. Last updated: 2/9/2016

MalaCards based summary: Dermatofibrosarcoma Protuberans, also known as dermatofibrosarcoma, is related to gastrointestinal stromal tumor and bednar tumor, and has symptoms including thickened skin, neoplasm of the skin and sarcoma. An important gene associated with Dermatofibrosarcoma Protuberans is PDGFB (Platelet Derived Growth Factor Subunit B), and among its related pathways are Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers and Striated Muscle Contraction. Affiliated tissues include the dermis laryer of the skin, skin and breast, and related mouse phenotypes are integument and cardiovascular system.

Disease Ontology:11 A fibrosarcoma that is located in the dermis laryer of the skin and that begins as a hard nodule and grows slowly.

Genetics Home Reference:25 Dermatofibrosarcoma protuberans is a rare type of cancer that causes a tumor in the deep layers of skin. This condition is a type of soft tissue sarcoma, which are cancers that affect skin, fat, muscle, and similar tissues.

OMIM:52 Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive, but rarely metastasizing tumor of the deep... (607907) more...

Wikipedia:71 Dermatofibrosarcoma protuberans (DFSP) is a very rare tumor. It is a rare neoplasm of the dermis layer... more...

Related Diseases for Dermatofibrosarcoma Protuberans

About this section

Diseases related to Dermatofibrosarcoma Protuberans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 193)
idRelated DiseaseScoreTop Affiliating Genes
1gastrointestinal stromal tumor27.7ACTC1, CD34, DES, PDGFRA, PDGFRB, S100B
2bednar tumor11.6
3myxofibrosarcoma11.4
4chromosome 4p duplication10.8COL1A1, PDGFB
5myoma10.7COL1A1, PDGFB
6auricular cancer10.7CD34, VIM
7transitional meningioma10.7F13A1, VIM
8progressive nodular histiocytosis10.7F13A1, S100B
9myopia10.7F13A1, VIM
10progressive myoclonus epilepsy, lafora type10.6PDGFB, PDGFRB
11hemangioma10.6F13A1, VIM
12hypotonia10.6S100B, VIM
13anaplastic oligoastrocytoma10.6S100B, VIM
14fraxf syndrome10.6S100B, VIM
15harding ataxia10.6DES, VIM
16classic mast cell leukemia10.6ACTC1, F13A1
17breast rhabdomyosarcoma10.6CD34, DES
18chiari malformation type 310.6ACTC1, F13A1
19pediatric fibrosarcoma10.6CD34, COL1A1, PDGFB
20lymphangiomatosis10.6ACTC1, VIM
21lymphocytic vasculitis10.6DES, VIM
22pediculus humanus capitis infestation10.5S100B, VIM
23malignant cystic nephroma10.5S100B, VIM
24soft tissue peripheral neuroepithelioma10.5DES, F13A1
25lumbar plexus neoplasm10.5S100B, VIM
26spindle cell liposarcoma10.5CD34, PDGFB
27anterograde amnesia10.5DES, VIM
28xq12-q13.3 duplication syndrome10.5ACTC1, DES
29anaplastic oligodendroglioma10.5ACTC1, NES
30tooth erosion10.5CD34, VIM
31subependymal giant cell astrocytoma10.5S100B, VIM
32premature aging syndrome, penttinen type10.5ACTC1, PDGFRB
33monophasic synovial sarcoma10.5DES, VIM
34infantile glycine encephalopathy10.5ACTC1, S100B
35bickerstaff brainstem encephalitis10.5DES, S100B
36diffuse pulmonary fibrosis10.5ACTC1, S100B
37subacute leukemia10.5DES, S100B
38intracystic papillary adenoma10.5NES, S100B
39childhood infratentorial neoplasm10.4PDGFB, TP53
40acquired porencephaly10.4PDGFRA, PDGFRB
41adult ependymoblastoma10.4CD34, TP53
42median neuropathy10.4CD34, TP53
43skin sarcoma10.4ACTC1, VIM
44focal chorioretinitis10.4DES, VIM
45vulvar alveolar soft part sarcoma10.4ACTC1, VIM
46relapsing epidemic typhus10.4PDGFRA, S100B
47osteopetrosis and infantile neuroaxonal dystrophy10.4NES, S100B, VIM
48ureter squamous cell carcinoma10.4CD34, TP53
49gallbladder adenoma10.4S100B, VIM
50adenomyoma of uterine corpus10.4NES, S100B, VIM

Graphical network of the top 20 diseases related to Dermatofibrosarcoma Protuberans:



Diseases related to dermatofibrosarcoma protuberans

Symptoms & Phenotypes for Dermatofibrosarcoma Protuberans

About this section


Clinical features from OMIM:

607907

Human phenotypes related to Dermatofibrosarcoma Protuberans:

 64 54 (show all 7)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thickened skin64 54 hallmark (90%) Very frequent (99-80%) HP:0001072
2 neoplasm of the skin64 54 hallmark (90%) Very frequent (99-80%) HP:0008069
3 sarcoma64 hallmark (90%) HP:0100242
4 skin ulcer64 54 typical (50%) Frequent (79-30%) HP:0200042
5 subcutaneous nodule54 Very frequent (99-80%)
6 erythema54 Very frequent (99-80%)
7 fibrosarcoma54 Very frequent (99-80%)

MGI Mouse Phenotypes related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107718.9CD34, COL1A1, PDGFB, PDGFRA, PDGFRB, S100B
2MP:00053858.1ACTC1, APOD, COL1A1, DES, F13A1, PDGFB
3MP:00053697.8ACTC1, COL1A1, DES, PDGFB, PDGFRA, PDGFRB
4MP:00107687.3ACTC1, APOD, COL1A1, DES, F13A1, HABP2
5MP:00053766.8ACTC1, APOD, CD34, COL1A1, DES, F13A1

Drugs & Therapeutics for Dermatofibrosarcoma Protuberans

About this section

Drugs for Dermatofibrosarcoma Protuberans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MechlorethamineapprovedPhase 337751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
╬▓,╬▓'-dichlorodiethyl-N-methylamine
2
IfosfamideapprovedPhase 33913778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
3
Doxorubicinapproved, investigationalPhase 3, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
4
DoxilApproved June 1999Phase 3, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
5Topoisomerase InhibitorsPhase 3, Phase 14945
6Alkylating AgentsPhase 3, Phase 14694
7Isophosphamide mustardPhase 3391
8Anti-Bacterial AgentsPhase 3, Phase 110884
9Antibiotics, AntitubercularPhase 3, Phase 16972
10Antineoplastic Agents, AlkylatingPhase 3, Phase 14474
11
Sunitinibapproved, investigationalPhase 2500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
12
Paclitaxelapproved, vet_approvedPhase 1, Phase 2275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
13Imatinib MesylatePhase 2, Phase 1594123596
14Protein Kinase InhibitorsPhase 2, Phase 13612
15
saracatinibPhase 232
Synonyms:
AZD 0530
 
AZD0530
saracatinib
16Angiogenesis InhibitorsPhase 24143
17Immunosuppressive AgentsPhase 2, Phase 112770
18Angiogenesis Modulating AgentsPhase 24072
19Antineoplastic Agents, PhytogenicPhase 1, Phase 25420
20Albumin-Bound PaclitaxelPhase 1, Phase 22757
21taxanePhase 1, Phase 2344
22Antimitotic AgentsPhase 1, Phase 25498
23tyrosineNutraceuticalPhase 1, Phase 2659
24
Cyclophosphamideapproved, investigationalPhase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
25Antirheumatic AgentsPhase 110627
26ImmunoglobulinsPhase 16045
27Antibodies, MonoclonalPhase 13795
28AntibodiesPhase 16045

Interventional clinical trials:

(show all 20)
idNameStatusNCT IDPhase
1Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaUnknown statusNCT00346164Phase 3
2Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue SarcomaUnknown statusNCT00334854Phase 3
3Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisUnknown statusNCT00555581Phase 2
4Neoadjuvant Imatinib in Dermatofibrosarcoma ProtuberansCompletedNCT00243191Phase 2
5Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1, Phase 2
6Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
7Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
8Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
9Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasCompletedNCT00474994Phase 2
10AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2
11Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1, Phase 2
12Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
13To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsRecruitingNCT01962103Phase 1, Phase 2
14Phase II Pazopanib Study in Advanced DermatofibrosarcomasTerminatedNCT01059656Phase 2
15Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue SarcomaTerminatedNCT00740597Phase 2
16Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00720174Phase 1
17Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
18Clinical Outcome of Pediatric Dermatofibrosarcoma ProtuberansUnknown statusNCT00173355
19Spanish Registry of Mohs SurgeryRecruitingNCT02310503
20Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for SarcomaWithdrawnNCT00334984

Search NIH Clinical Center for Dermatofibrosarcoma Protuberans


Cochrane evidence based reviews: dermatofibrosarcoma

Genetic Tests for Dermatofibrosarcoma Protuberans

About this section

Genetic tests related to Dermatofibrosarcoma Protuberans:

id Genetic test Affiliating Genes
1 Dermatofibrosarcoma Protuberans27 24 PDGFB

Anatomical Context for Dermatofibrosarcoma Protuberans

About this section

MalaCards organs/tissues related to Dermatofibrosarcoma Protuberans:

36
Skin, Breast, Lung, Bone, Lymph node, Endothelial, Pancreas

FMA organs/tissues related to Dermatofibrosarcoma Protuberans:

17
The dermis laryer of the skin

Publications for Dermatofibrosarcoma Protuberans

About this section

Articles related to Dermatofibrosarcoma Protuberans:

(show top 50)    (show all 629)
idTitleAuthorsYear
1
Incidence and Outcomes of Dermatofibrosarcoma Protuberans in the US Pediatric Population. (27922973)
2017
2
A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience. (27749444)
2017
3
A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. (28056985)
2017
4
Scalp Dermatofibrosarcoma Protuberans: A Potential Diagnostic Pitfall. (26967087)
2016
5
Pedunculated Nodules as a Variant of Dermatofibrosarcoma Protuberans. (27746644)
2016
6
Dermatofibrosarcoma protuberans of the scalp, with fibrosarcomatous areas masquerading as epidermal inclusion cyst. (27389726)
2016
7
Congenital atrophic dermatofibrosarcoma protuberans detected by COL1A1-PDGFB rearrangement. (26932148)
2016
8
Dermoscopy of dermatofibrosarcoma protuberans on black skin. (27185450)
2016
9
Usefulness of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in dermatofibrosarcoma protuberans on treatment with imatinib. (27385888)
2016
10
Transformation of Dermatofibrosarcoma Protuberans into a Fibrosarcoma. (26955135)
2016
11
Dermatofibrosarcoma protuberans post basal cell carcinoma excision: A case report. (27494371)
2016
12
Improving precision of resection by pre-surgery inspections with contrast-enhanced ultrasound for dermatofibrosarcoma protuberans. (27572421)
2016
13
Hormone receptor expression in patients with dermatofibrosarcoma protuberans. (27542587)
2016
14
Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. (27608549)
2016
15
Dermatofibrosarcoma Protuberans: Wide Local Excision Versus Mohs Micrographic Surgery. (27591501)
2016
16
Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans. (27262160)
2016
17
Imaging Features of Breast Dermatofibrosarcoma Protuberans in Various Modalities Including FDG-PET CT. (27703659)
2016
18
Nodular Fasciitis Complicating a Staged Surgical Excision of Dermatofibrosarcoma Protuberans. (28018683)
2016
19
Dermatofibrosarcoma Protuberans: A comprehensive review on the spectrum of clinico-radiological presentations. (27753236)
2016
20
Myxoid Dermatofibrosarcoma Protuberans of the Abdomen. (26816559)
2016
21
Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. (27806849)
2016
22
InA vivo characterization of recurrent dermatofibrosarcoma protuberans by dermoscopy and reflectance confocal microscopy. (27745647)
2016
23
Dermatofibrosarcoma Protuberans: Insights into a Rare Soft Tissue Tumor. (27195182)
2016
24
Fibrosarcomatous change in the background of dermatofibrosarcoma protuberans in male breast: Study of a rare case and review of the entity. (27134483)
2016
25
A rare case of dermatofibrosarcoma protuberans of the forefoot. (27257461)
2016
26
Dermatofibrosarcoma Protuberans-Like Tumor With COL1A1 Copy Number Gain in the Absence of t(17;22). (27984233)
2016
27
Paraffin-embedded micrographic surgery for the treatment of dermatofibrosarcoma protuberans: Analysis of 33 patients. (27643548)
2016
28
Clinicopathological features of dermatofibrosarcoma protuberans. (26870263)
2016
29
Prognostic Factors of Survival in Dermatofibrosarcoma Protuberans. (27973651)
2016
30
Dermatofibrosarcoma protuberans: a case report and review of the literature. (27895450)
2016
31
A Case of Dermatofibrosarcoma Protuberans Arising in Subcutaneous Tissue of the Breast. (27346162)
2016
32
A Challenging Giant Dermatofibrosarcoma Protuberans on the Face. (27437151)
2016
33
Medallion-Like Dermal Dendrocytic Hamartoma, Dermatofibrosarcoma Protuberans, and Adenosine Deaminase-Deficient Severe Combined Immunodeficiency. (27176810)
2016
34
Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. (27256159)
2016
35
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy. (27988943)
2016
36
Histologic Features Associated with Deep Invasion in Dermatofibrosarcoma Protuberans. (26944448)
2016
37
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation. (27828659)
2016
38
Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases. (27580559)
2016
39
Operative management of dermatofibrosarcoma protuberans of the breast. (27365884)
2016
40
Case of pigmented dermatofibrosarcoma protuberans with atrophic change. (27029004)
2016
41
Risk factors for distant metastasis of dermatofibrosarcoma protuberans. (27289468)
2016
42
Dermatofibrosarcoma protuberans-a rare neoplasm. (27190778)
2016
43
Prognostic Factors of Survival in Dermatofibrosarcoma Protuberans-Reply. (27973652)
2016
44
Dermatofibrosarcoma Protuberans. (27542641)
2016
45
The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis. (26879523)
2016
46
An unusual presentation of Dermatofibrosarcoma Protuberans with pleomorphic sarcomatous transformation: potential pitfall and diagnostic strategy. (26955897)
2016
47
Bednar Tumor (Pigmented Dermatofibrosarcoma Protuberans). (26945477)
2016
48
Dermatoscopic findings of atrophic dermatofibrosarcoma protuberans. (25692086)
2015
49
Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. (26276213)
2015
50
Pigmented Dermatofibrosarcoma Protuberans and Blue Naevi with Similar Dermoscopy: A Case Report. (26258458)
2015

Variations for Dermatofibrosarcoma Protuberans

About this section

Clinvar genetic disease variations for Dermatofibrosarcoma Protuberans:

5
id Gene Variation Type Significance SNP ID Assembly Location
1PDGFBPDGFB, PDGFB/COL1A1 FUSIONundetermined variantPathogenicChr na, -1: -1

Cosmic variations for Dermatofibrosarcoma Protuberans:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM575NRASsoft tissue,skin,sarcoma,NSc.38G>Cp.G13A8
2COSM584NRASskin,shoulder,benign melanocytic nevus,congenitalc.182A>Gp.Q61R6
3COSM476BRAFskin,trunk,benign melanocytic nevus,congenitalc.1799T>Ap.V600E6
4COSM28757GNAQsoft tissue,chest,haemangioma,congenitalc.626A>Tp.Q209L4

Expression for genes affiliated with Dermatofibrosarcoma Protuberans

About this section
Search GEO for disease gene expression data for Dermatofibrosarcoma Protuberans.

Pathways for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

Pathways related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
19.7CD34, DES, PDGFB
29.6ACTC1, DES, VIM
3
Show member pathways
9.5DES, NES, VIM
4
Show member pathways
9.5PDGFB, PDGFRA, PDGFRB
59.5PDGFB, PDGFRA, PDGFRB
69.5PDGFB, PDGFRA, PDGFRB
79.3NES, PDGFB, PDGFRB, VIM
89.3COL1A1, PDGFB, PDGFRA, PDGFRB
99.2PDGFRA, PDGFRB, TP53
10
Show member pathways
9.0PDGFB, PDGFRA, PDGFRB, TP53
11
Show member pathways
9.0PDGFB, PDGFRA, PDGFRB, TP53
129.0PDGFB, PDGFRA, PDGFRB, TP53
139.0PDGFB, PDGFRA, PDGFRB, TP53
148.7COL1A1, PDGFB, PDGFRA, PDGFRB, TP53
158.7NES, PDGFB, PDGFRA, S100B, VIM
168.7PDGFB, PDGFRA, PDGFRB, TP53, VIM

GO Terms for genes affiliated with Dermatofibrosarcoma Protuberans

About this section

Cellular components related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular matrixGO:003101210.1COL1A1, NES, PDGFB, VIM
2intermediate filamentGO:000588210.0DES, NES, VIM
3intermediate filament cytoskeletonGO:004511110.0DES, NES, VIM
4platelet alpha granule lumenGO:00310939.5F13A1, PDGFB, SERPINA3
5extracellular spaceGO:00056158.5ACTC1, APOD, COL1A1, HABP2, PDGFB, S100B
6extracellular regionGO:00055767.6APOD, CD163, CD34, COL1A1, F13A1, HABP2

Biological processes related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

(show all 29)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of calcium ion importGO:009028010.7PDGFB, PDGFRB
2positive regulation of chemotaxisGO:005092110.7PDGFB, PDGFRB
3positive regulation of DNA biosynthetic processGO:200057310.7PDGFB, PDGFRB
4paracrine signalingGO:003800110.7CD34, PDGFB
5positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayGO:003579310.7PDGFB, PDGFRB
6intermediate filament organizationGO:004510910.6DES, VIM
7response to hyperoxiaGO:005509310.5COL1A1, PDGFRB
8negative regulation of platelet activationGO:001054410.5PDGFB, PDGFRA
9metanephric glomerular capillary formationGO:007227710.4PDGFRA, PDGFRB
10positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.4PDGFRA, PDGFRB
11positive regulation of phospholipase C activityGO:001086310.4PDGFRA, PDGFRB
12muscle filament slidingGO:003004910.3ACTC1, DES, VIM
13stem cell proliferationGO:007208910.3CD34, NES
14platelet degranulationGO:000257610.3F13A1, PDGFB, SERPINA3
15retina vasculature development in camera-type eyeGO:006129810.2PDGFRA, PDGFRB
16cell chemotaxisGO:006032610.2PDGFB, PDGFRA, PDGFRB
17phosphatidylinositol phosphorylationGO:004685410.2PDGFB, PDGFRA, PDGFRB
18phosphatidylinositol-mediated signalingGO:004801510.2PDGFB, PDGFRA, PDGFRB
19platelet-derived growth factor receptor signaling pathwayGO:004800810.2PDGFB, PDGFRA, PDGFRB
20positive regulation of fibroblast proliferationGO:004814610.2PDGFB, PDGFRA, PDGFRB
21positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.2PDGFB, PDGFRA, PDGFRB
22positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.2PDGFB, PDGFRA, PDGFRB
23positive regulation of reactive oxygen species metabolic processGO:200037910.2PDGFB, PDGFRB, TP53
24regulation of phosphatidylinositol 3-kinase signalingGO:001406610.1PDGFB, PDGFRA, PDGFRB
25cardiac myofibril assemblyGO:005500310.1ACTC1, PDGFRA, PDGFRB
26positive regulation of cell migrationGO:003033510.0COL1A1, PDGFB, PDGFRA, PDGFRB
27response to drugGO:00424939.9ACTC1, APOD, COL1A1, PDGFB
28positive regulation of gene expressionGO:00106289.5ACTC1, CD34, PDGFB, TP53, VIM
29wound healingGO:00420609.3COL1A1, PDGFB, PDGFRA, PDGFRB

Molecular functions related to Dermatofibrosarcoma Protuberans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.1PDGFB, PDGFRA, PDGFRB
2platelet-derived growth factor receptor bindingGO:000516110.0PDGFB, PDGFRA, PDGFRB
3platelet-derived growth factor bindingGO:00484079.8COL1A1, PDGFB, PDGFRA, PDGFRB
4vascular endothelial growth factor bindingGO:00380859.7PDGFRA, PDGFRB
5Ras guanyl-nucleotide exchange factor activityGO:00050889.6PDGFB, PDGFRA, PDGFRB
6identical protein bindingGO:00428029.2COL1A1, DES, PDGFB, S100B, TP53, VIM

Sources for Dermatofibrosarcoma Protuberans

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet